73831-13-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyano-3-methylbenzoic acid is used as a reactant for the preparation of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones. These compounds are significant because they serve as inhibitors of group A streptococcal streptokinase expression. By inhibiting the expression of streptokinase, a key enzyme in the pathogenesis of group A streptococcal infections, 4-cyano-3-methylbenzoic acid contributes to the development of potential therapeutic agents for treating such infections.

InChI:InChI=1/C9H7NO2/c1-6-4-7(9(11)12)2-3-8(6)5-10/h2-4H,1H3,(H,11,12)

Upstream product

• 21789-36-6 2,4-dimethylbenzonitrile 
• 55984-93-5 2-methyl-1,4-dicyanobenzene 
• 7664-93-9 sulfuric acid 
• 2486-70-6 4-amino 3-methylbenzoic acid 
• 124-38-9 carbon dioxide 
• 67832-11-5 4-bromo-2-methylbenzonitrile 
• 109-72-8 n-butyllithium 
• 748101-41-9 zinc cyanide 
• 7697-28-1 4-bromo-3-methylbenzoic acid 

Downstream Products

• 5156-01-4 2-methylterephthalic acid 
• 1160759-52-3 4-cyano-3-methylbenzoyl chloride 
• 335155-20-9 1-(4-Cyano-3-methylbenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 128069-80-7 2-(4-Cyano-3-methylphenyl)-5,6,7,8-tetrahydro-4H-thiazolo[5,4-b]azepine hydrochloride 
• 384832-33-1 4-(4-Cyano-3-methylbenzoyl)-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine 
• 384831-95-2 1-(4-Cyano-3-methylbenzoyl)-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 384831-99-6 1-(4-Cyano-3-methylbenzoyl)-5-(3-pyridyl)methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 384832-23-9 1-(4-Cyano-3-methylbenzoyl)-5-ethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 384832-29-5 5-(4-Cyano-3-methylbenzoyl)-2,3,4,5-tetrahydro-1,5-benzothiazepine 
• 1085938-52-8 C₂₇H₂₄N₆O₃ 
• 479234-62-3 2-methyl-4-(1-methyl-1,3a,4,5,10,10a-hexahydrobenzo[b]-pyrazolo[3,4-e][1,4]diazepine-5-carbonyl)benzonitrile 
• 500013-44-5 5-(4-cyano-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepine 
• 1267507-78-7 4-cyano-N-[2-ethyl-4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-6-methylphenyl]-3-methylbenzamide 
• 1267505-51-0 tert-butyl (4-{[2-ethyl-4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-6-methylphenyl]carbamoyl}-2-methylbenzyl)carbamate 

Relevant academic research and scientific papers

Structure–Affinity Relationships of Fluorinated Spirocyclic σ2 Receptor Ligands with an Exocyclic Benzylamino Moiety

To identify a potent and selective σ2 receptor ligand appropriate for development as a positron emission tomography (PET) tracer, several fluorinated analogues of the spirocyclic lead compounds trans- and cis-6 (N-(2,4-dimethylbenzyl)-3-methoxy

Heteroarylacetic phenylbenzamide, composition and method of use (by machine translation)

Provided are certain heteroaryl benzamides, compositions, and methods of their manufacture and use.

MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL

Compounds comprising piperazines, piperidines, spiro-furanopiperidines, and analogs thereof are provided that are modulators, such as positive allosteric modulators, of one or more subclasses of vasopressin receptors. The compounds can be selective modulators of one or more subclasses of vasopressin receptors. Compounds of the invention can be used in the treatment of a condition wherein modulating a vasopressin receptor is medically indicated for treatment of the condition.

Novel inhibitors of bacterial virulence: Development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression

Resistance to antibiotics is an increasingly dire threat to human health that warrants the development of new modes of treating infection. We recently identified 1 (CCG-2979) as an inhibitor of the expression of streptokinase, a critical virulence factor in Group A Streptococcus that endows blood-borne bacteria with fibrinolytic capabilities. In this report, we describe the synthesis and biological evaluation of a series of novel 5,6-dihydrobenzo[h] quinazolin-4(3H)-one analogs of 1 undertaken with the goal of improving the modest potency of the lead. In addition to achieving an over 35-fold increase in potency, we identified structural modifications that improve the solubility and metabolic stability of the scaffold. The efficacy of two new compounds 12c (CCG-203592) and 12k (CCG-205363) against biofilm formation in Staphylococcus aureus represents a promising additional mode of action for this novel class of compounds.

PESTICIDAL CARBOXAMIDES

The object of the present invention is to provide novel carboxamides which exhibit an excellent pesticidal activity as pesticides. Disclosed are the carboxamides represented by the following Formula (I) wherein each substituent is as defined in the specif

NEW 2-AMIDOTHIADIAZOLE DERIVATIVES

New 2-amidothiadiazole derivatives having the chemical structure of formula (I) or pharmaceutically acceptable salts or N-oxides thereof as agonists of S1P1 receptors.

New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists

Vasopressin (AVP) is a hormone that stimulates an increase in water permeability through activation of V2 receptors in the kidney. The analogue of AVP, desmopressin, has proven an effective drug for diseases where a reduction of urine output is desired. However, its peptidic nature limits its bioavailability. We report herein the discovery of potent, nonpeptidic, benzylurea derived agonists of the vasopressin V2 receptor. We describe substitutions on the benzyl group to give improvements in potency and subsequent modifications to the urea end group to provide improvements in solubility and increased oral efficacy in a rat model of diuresis. The lead compound 20e (VA106483) is reported for the first time and has been selected for clinical development.

HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS

The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

Piperazines as oxytocin agonists

Disclosed are novel compounds according to general formula I, which have shown OT agonist activity.

Fused azepine derivatives and their use as antidiuretic agents

Compounds according to general formulae (1 and 2), wherein G1 is an azepine derivative and G2 is a group according to general formulae (9-11) are new. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.